AMITRIPTYLINE 10 & 50mg: NDMA and NNORT impurity
Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.
See affected DINs and lot numbers on Health Canada ↗Why it was recalled
Contamination
What you should do
- Continue taking your medication.
- Not treating a condition may pose a greater health risk than potential nitrosamine exposure.
- Contact your health care provider:to discuss treatment options if you're using a recalled productif you have taken a recalled product and are concerned about your healthAsk your pharmacist if you're not sure if the product you're taking has been recalled.
Other Recent Recalls
PDP-DIPHENHYDRAMINE
PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)
Type II2026-11-09
Moderate health risk
Unauthorized injectable peptide and non-peptide drugs
Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs
2026-11-06
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks
2026-11-03
Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.